0001415889-24-009625.txt : 20240401
0001415889-24-009625.hdr.sgml : 20240401
20240401212828
ACCESSION NUMBER: 0001415889-24-009625
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240328
FILED AS OF DATE: 20240401
DATE AS OF CHANGE: 20240401
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Zinda Michael
CENTRAL INDEX KEY: 0001815366
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39335
FILM NUMBER: 24812002
MAIL ADDRESS:
STREET 1: C/O REPARE THERAPEUTICS INC.
STREET 2: 7210 FREDERICK-BANTING, SUITE 100
CITY: ST-LAURENT
STATE: A8
ZIP: H4S 2A1
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Repare Therapeutics Inc.
CENTRAL INDEX KEY: 0001808158
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: Z4
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7171 FREDERICK BANTING
STREET 2: SUITE 270, BUILDING 2
CITY: SAINT-LAURENT
STATE: A8
ZIP: H4S 1Z9
BUSINESS PHONE: (857) 412-7018
MAIL ADDRESS:
STREET 1: 7171 FREDERICK BANTING
STREET 2: SUITE 270, BUILDING 2
CITY: SAINT-LAURENT
STATE: A8
ZIP: H4S 1Z9
4
1
form4-04022024_010422.xml
X0508
4
2024-03-28
0001808158
Repare Therapeutics Inc.
RPTX
0001815366
Zinda Michael
C/O REPARE THERAPEUTICS INC.
ST-LAURENT
A8
H4S 1Z9
QUEBEC, CANADA
false
true
false
false
EVP, CHIEF SCIENTIFIC OFFICER
1
Common Shares
2024-03-28
4
S
0
450
4.64
D
72318
D
Common Shares
2024-04-01
4
S
0
410
4.66
D
71908
D
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 24,550 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on February 1, 2023, of which 8,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.38 to $4.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.53 to $4.76 inclusive.
/s/ Steve Forte, Attorney-in-Fact
2024-04-01